IDL Biotech signs distributor agreement in Ghana
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.
We would like to inform you that our office will be closed, due to Christmas and New Years Holidays during the following period December 22nd 2019 to January 5th, 2020. Full operations will resume on January the 6th.
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.